<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03301597</url>
  </required_header>
  <id_info>
    <org_study_id>NLA-0101-CIN-01</org_study_id>
    <nct_id>NCT03301597</nct_id>
  </id_info>
  <brief_title>NLA101 in Adults Receiving High Dose Chemotherapy for AML</brief_title>
  <acronym>LAUNCH</acronym>
  <official_title>A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nohla Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nohla Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and
      efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects
      with AML.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and
      efficacy of NLA101 to reduce the rate of infections associated with chemotherapy induced
      neutropenia (CIN) in adult subjects with AML.

      Eligible subjects with untreated de novo or secondary AML and per local institutional
      standards planned to receive at least two cycles of chemotherapy with curative intent will be
      enrolled into the study and randomized 1:1:1:1 to 1 of 3 Investigational Arms (Standard of
      Care [SOC] chemotherapy + low, medium, or high dose NLA101) or a Control Arm (SOC
      chemotherapy).

      Subjects randomized to an Investigational Arm will be eligible to receive a single fixed
      assigned dose of NLA101 after the first cycle of chemotherapy, and up to 2 additional
      identical cell doses after subsequent chemotherapy cycles (one NLA101 infusion per cycle).
      Subjects randomized to the Control Arm will be followed for up to 3 cycles of chemotherapy.

      All subjects will be followed for 84 days following randomization, or 30 days post final
      infusion of NLA101, or 30 days post the day after the last chemotherapy infusion for Control
      Arm, whichever is longer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to 1 of 3 Investigational Arms or a Control Arm in a 1:1:1:1 ratio.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>This is an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Event Rate of Grade 3 or Higher Bacterial or Fungal Infection</measure>
    <time_frame>From randomization through follow-up of 84 days post randomization, 30 days post last infusion of NLA101, or 30 days post last infusion of chemotherapy for Control Arm, whichever is later</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event rate of grade 3 or higher documented bacterial and fungal infections per cycle of chemotherapy</measure>
    <time_frame>From randomization through follow-up of 84 days post randomization, 30 days post last infusion of NLA101, or 30 days post last infusion of chemotherapy for Control Arm, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of filgrastim (or biosimilar) administration</measure>
    <time_frame>From randomization through follow-up of 84 days post randomization, 30 days post last infusion of NLA101, or 30 days post last infusion of chemotherapy for Control Arm, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>From randomization through follow-up of 84 days post randomization, 30 days post last infusion of NLA101, or 30 days post last infusion of chemotherapy for Control Arm, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of complications due to infections</measure>
    <time_frame>From randomization through follow-up of 84 days post randomization, 30 days post last infusion of NLA101, or 30 days post last infusion of chemotherapy for Control Arm, whichever is later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of grade 3 or higher fever or hypothermia</measure>
    <time_frame>From randomization through follow-up of 84 days post randomization, 30 days post last infusion of NLA101, or 30 days post last infusion of chemotherapy for Control Arm, whichever is later</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NLA101</intervention_name>
    <description>NLA101 is a universal donor &quot;off-the-shelf&quot; ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use.</description>
    <arm_group_label>Low Dose Arm</arm_group_label>
    <arm_group_label>Medium Dose Arm</arm_group_label>
    <arm_group_label>High Dose Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care (SOC) chemotherapy</intervention_name>
    <description>The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Low Dose Arm</arm_group_label>
    <arm_group_label>Medium Dose Arm</arm_group_label>
    <arm_group_label>High Dose Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Criteria:

        Inclusion Criteria:

          -  Age â‰¥ 18 (or legal age of majority for sites outside US).

          -  Untreated de novo or secondary acute myeloid leukemia (AML), including AML that has
             progressed from myelodysplastic syndrome (MDS), and histologically documented
             diagnosis

          -  Eligible for at least 2 cycles of standard of care AML chemotherapy that will result
             in moderate to severe myelosuppression and have curative intent

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 or
             Karnofsky Status of 50 to 100.

          -  Adequate cardiac, renal, and hepatic functions.

        Exclusion Criteria:

          -  Extramedullary disease in the absence of bone marrow or blood involvement

          -  Acute promyelocytic leukemia (APL) with PML-RARA

          -  Prior AML therapy, with the exception of intrathecal chemotherapy or emergent
             radiation for myeloid sarcoma.

          -  Concurrent malignancy requiring active treatment with chemotherapy, immunotherapy, or
             radiation

          -  Prior allotransplant, including allogeneic hematopoietic cell transplant or solid
             organ allogeneic transplant

          -  Known hypersensitivity or history of hypersensitivity to dimethylsulfoxide (DMSO)

          -  Active/chronic human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
             hepatitis B virus (HBV) infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin S Tallman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naval G Daver, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richie Phan, CTM</last_name>
    <phone>206-519-5318</phone>
    <email>RichieP@NohlaTherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Colleen Delaney, MD, Founder &amp; CMO</last_name>
    <phone>206-519-5304</phone>
    <email>ColleenD@NohlaTherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Eddings, BS, CCRP</last_name>
      <phone>916-734-3604</phone>
      <email>ckeddings@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Mehrdad Abedi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, St. Matthews Campus</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J Maly, MD</last_name>
      <phone>502-899-3366</phone>
      <email>Joseph.Maly@NortonHealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Joseph J Maly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Munoz</last_name>
      <phone>631-638-0844</phone>
      <email>CancerClinicalTrials@StonyBrookMedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salman Fazal, MD</last_name>
      <phone>412-578-4355</phone>
      <email>Salman.Fazal@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Salman Fazal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naval G Daver, MD</last_name>
      <phone>713-794-4392</phone>
      <email>NDaver@MDAnderson.org</email>
    </contact>
    <investigator>
      <last_name>Naval G Daver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peiman Hematti, MD</last_name>
      <phone>608-265-0106</phone>
      <email>pxh@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Peiman Hematti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy-induced Neutropenia</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Fungal Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

